25Jul/13

Gilead Sciences Announces Second Quarter 2013 Financial Results – DailyFinance

Gilead Sciences Announces Second Quarter 2013 Financial Results
DailyFinance
Results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101) in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia. This regimen achieved a complete response rate of 19 percent and an 
Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call Seeking Alpha

all 24 news articles »

25Jul/13

Bullfeathers' philosophers to address bioethical concerns – University at Buffalo Reporter


University at Buffalo Reporter

Bullfeathers’ philosophers to address bioethical concerns
University at Buffalo Reporter
The conference, which will take place from 8:30 a.m. to 5:30 p.m. in 280 Park Hall, will address four principle areas: death, brain death and the human identity problem; intention, consent and responsibility; health, development and disease; and harm,